Hyperhidrosis Treatment Market Research, 2031
The global hyperhidrosis treatment market was valued at $575.3 million in 2021, and is projected to reach $950.7 million by 2031, growing at a CAGR of 5.1% from 2022 to 2031. A disorder called hyperhidrosis, is characterized by profuse sweating. One part of the body may experience excessive perspiration, or the entire body. Controlling the symptoms of hyperhidrosis can be a constant struggle for many people. Hyperhidrosis patients seem to have excessively active sweat glands. Uncontrollable sweating can cause severe physical and emotional distress. The cause of hyperhidrosis is frequently unidentified, and it is generally believed to be the result of a disturbance with the portion of the nervous system that regulates sweating. Even while it's not life-threatening, it could still be unpleasant and embarrassing, leading to mental trauma. Hyperhidrosis can either occur later in life or be present at birth. However, the majority of cases of excessive sweating usually begin while a person is a teenager.
The drivers contributing to the growth of the hyperhidrosis treatment market include an increase disease prevalence especially axillary hyperhidrosis in developed countries. In addition, globally expanding product launches and product approvals as well as rising demand for healthcare services is anticipated to significantly fuel market growth. Surge in utilization topical treatment also propels the hyperhidrosis treatment market growth. Many are adopting strategies like agreement and collaboration for growth of the market. Significant surge in the incidence of hyperhidrosis is one leading factors of this market and one of the great opportunities for the players to invest in hyperhidrosis treatment market forecast.
Furthermore, the pace of technological advancement and increasing demand for the treatment of hyperhidrosis creates a lucrative hyperhidrosis treatment market opportunity in emerging economies. However, lack of awareness and unfavorable reimbursement scenario is expected to hinder the hyperhidrosis treatment industry.
Impact of COVID-19
The COVID-19 pandemic is anticipated to have a negative impact on the growth of the global market for hyperhidrosis treatments. However, during the pandemic, despite the recommendations to maintain social distance, many patients treated their illnesses using self-medication or other unconventional methods. Patients with hyperhidrosis had a disproportionately higher rate of depression during the pandemic, particularly among female patients, and some of these patients reported difficulty receiving therapy during the pandemic.
Hyperhidrosis Treatment Market Segmentation
The hyperhidrosis treatment market is segmented on the basis of type, treatment age, and region. On the basis of type, the market is categorized into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, others. By treatment, it is divided into botulinum toxin injection, topical treatment and oral medication. Oral medication is further bifurcated as anticholinergics and others. By age, it is segmented into below 50 years and above 50 years. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Segment Review
By type, the market is segmented into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, and others. The axillary hyperhidrosis segment generated maximum revenue in 2021, and also expected to witness highest CAGR of during the forecast period, owing to high incidence of axillary hyperhidrosis.
Depending on treatment, the market is divided into botulinum toxin injection, topical treatment and oral medication. The topical treatment segment dominated the hyperhidrosis treatment market size in 2021, and also expected to witness highest CAGR of during the forecast period owing to significant product innovation.
Depending on age, the market is divided into below 50 years and above 50 years. The below 50 years segment dominated the hyperhidrosis treatment market size in 2021, and also expected to witness highest CAGR during the forecast period owing to incidence of disease in more in below 50-year age group.
Region wise, North America accounted for a majority of the global hyperhidrosis treatment market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in hyperhidrosis treatment, high incidence of disease, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing rise in patient population, development of healthcare infrastructure and increase in investments projects in the region.
The major players profiled in the report are AbbVie Inc, Avanor Healthcare Ltd , Brickbell Biotech, Inc , Dr August Wolff GmbH & Co. Kg Drugs, Dr. Reddy's Laboratories Ltd, Eirion Therapeutics, Inc, Eli Lilly and Company, Hugel, Inc., Kaken Pharmaceutical Co., Ltd, Intas Pharmaceuticals Ltd, Roivant Sciences Ltd., and Theravida, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperhidrosis treatment market analysis from 2021 to 2031 to identify the prevailing hyperhidrosis treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the hyperhidrosis treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global hyperhidrosis treatment market trends, key players, market segments, application areas, and market growth strategies.
Hyperhidrosis Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 950.7 million |
 Growth Rate | CAGR of 5.1% |
 Forecast period | 2021 - 2031 |
 Report Pages | 281 |
 By Type |
|
 By Treatment |
|
 By Age |
|
 By Region |
|
 Key Market Players | Eli Lilly and Company, Roivant Sciences Ltd., Brickbell Biotech, Inc, AbbVie Inc., Dr August Wolff Gmbh & Co. Kg Drugs, Intas Pharmaceuticals Ltd, Dr. Reddy's Laboratories Ltd., Hugel, Inc, Avanor Healthcare Ltd, Eirion Therapeutics, Inc, Kaken Pharmaceutical Co., Ltd., Theravida, Inc |
Analyst Review
This section provides opinions of top level CXOs in the global hyperhidrosis treatment market. According to the insights of CXOs of leading companies in the market, development of advanced and reliable hyperhidrosis treatment systems has led to extensive number of treatments of this disease.
The hyperhidrosis treatment industry holds high potential owing to innovative concepts and multidisciplinary expertise demand for new technological advancements in the development of hyperhidrosis treatment. The recommendations for them are anticipated to expand with the introduction of new drugs with less side effects. Increasing incidence of hyperhidrosis creates a lucrative opportunity for market players to invest in this market.
Rise in incidence of hyperhidrosis and surge in product launch & product approval are the factors attributed to the growth of hyperhidrosis treatment market.
Topical treatments is the leading treatment of hyperhidrosis market.
The global hyperhidrosis treatment market was valued at $575.3 million in 2021, and is estimated to reach $ 950.7 million by 2031, growing at a CAGR of 5.1% from 2022 to 2031.
2021 is the base year of the hyperhidrosis treatment market.
AbbVie Inc, Avanor Healthcare Ltd , Brickbell Biotech, Inc , Dr August Wolff GmbH & Co. Kg Drugs, Dr. Reddy's Laboratories Ltd, Eirion Therapeutics, Inc, Eli Lilly and Company, Hugel, Inc., Kaken Pharmaceutical Co., Ltd, Intas Pharmaceuticals Ltd, Roivant Sciences Ltd., and Theravida, Inc. are the top companies to hold the market share in hyperhidrosis treatment.
North America is the largest regional market for hyperhidrosis treatment.
2022 to 2031 is the forecast year of the hyperhidrosis treatment market.
Loading Table Of Content...
